Canadian Company Groupe RSL Produces Canada’s First Lab-Grown Diamond Gem
20.9.2022 14:30:00 EEST | Business Wire | Press release
Groupe RSL is the first company to produce a Canadian lab-grown diamond gem, at its production facility in Quebec. The company is currently producing large diamonds for the premium jewellery market. With sustainability at the heart of its approach, Groupe RSL believes that lab diamonds have the potential to significantly reduce the environmental impacts of diamond production.
“Laboratory diamonds have the potential to revolutionize the industry, while reducing the environmental and human costs associated with diamond production,” said Luke Sinclair, CFO of Groupe RSL. “Consumers are seeking greater transparency in the diamonds that they purchase, and we firmly believe that the industry need not be at odds with the environment or principles of social responsibility. We are excited to see how the lab-grown diamond industry evolves over the coming years.”
Groupe RSL produces its diamonds locally in Quebec using a chemical vapour deposition, or CVD, process, whereby hydrogen and methane gas are combined in a plasma under precise conditions to grow diamonds one atom at a time over a period of several weeks to a month. Powered entirely by hydroelectricity, Groupe RSL has developed its own unique process to become the first Canadian company to use this approach to make diamond gems.
“For most of human scientific history, we thought that it was impossible to make diamonds in anything but the hottest high-pressure conditions. That’s why early attempts at man-made diamond focused on replicating the intense pressure that creates diamonds beneath the ground,” adds Sinclair. “Recent research has brought to light a new idea, using hydrogen and methane gas in a controlled reaction.”
Mined diamonds vs. lab-created diamonds
Mined diamonds and lab created diamonds are identical—chemically, physically and optically, and cannot be distinguished from one another without highly specialized equipment. In fact, mined diamonds often contain defects or impurities, both of which can be controlled or removed in lab diamonds.
Consumer shift
There has been a significant increase in demand for lab-grown diamonds in recent years, with lab diamond’s share of diamond sales more than doubling between 2020 and 2022.1 Millennials and Generation Z are moving away from mined diamonds, with nearly 70% of millennials considering buying a lab grown alternative.2 Consumers also seek greater transparency to ensure diamonds are sourced responsibly and produced sustainably. For example, nine in ten Generation Z consumers believe companies have a responsibility to address environmental and social issues.
About Groupe RSL Inc.
Groupe RSL Inc. is an innovative producer of diamond and the only Canadian producer of lab diamonds for the jewellery market. The company produces diamonds using a unique CVD process and technology. Groupe RSL produces beautiful and sustainable Canadian diamonds at its Quebec-based facility which is powered by 100% hydroelectricity. While their diamonds last forever, the company is committed to ensuring their ecological and social footprint does not. For more information, visit www.groupersl.com.
__________________________
1 Diamond industry analyst Edahn Golan. https://www.gemsociety.org/news/2022/05/18/interest-lab-grown-diamonds-surging-shows-no-signs-of-stopping/#:~:text=In%202020%2C%20lab%20diamond's%20share,be%20expected%2C%E2%80%9D%20said%20Golan
2 Millennial Consumer Research Lab Grown Diamonds, MVI Marketing LLC, May 3, 2018.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005008/en/
Contact information
Eric Aach
514-569-3594
eaach@national.ca
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom